113 related articles for article (PubMed ID: 25923513)
1. 5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors.
Xiang P; Jie H; Zhou Y; Yang B; Wang HJ; Hu J; Hu J; Yang SY; Zhao YL
Molecules; 2015 Apr; 20(5):7620-36. PubMed ID: 25923513
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
3. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
[TBL] [Abstract][Full Text] [Related]
4. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
5. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
6. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract][Full Text] [Related]
7. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
Momparler RL; Côté S
Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
Cai J; You H; Qin X; Wang Y; Li W
Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135
[TBL] [Abstract][Full Text] [Related]
9. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract][Full Text] [Related]
11. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
12. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
[TBL] [Abstract][Full Text] [Related]
13. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
15. SAH derived potent and selective EZH2 inhibitors.
Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and potential anti-proliferative activity of some novel 4-aminoquinoline derivatives.
Ghorab MM; Al-Said MS; Arafa RK
Acta Pharm; 2014 Sep; 64(3):285-97. PubMed ID: 25296675
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
19. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
